Form 8-K - Current report:
SEC Accession No. 0001493152-24-043322
Filing Date
2024-11-01
Accepted
2024-11-01 16:05:18
Documents
28
Period of Report
2024-11-01
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43960
2 ex99-1.htm EX-99.1 317043
3 ex99-2.htm EX-99.2 313467
4 ex99-1_001.jpg GRAPHIC 17643
5 ex99-1_002.jpg GRAPHIC 10819
6 ex99-1_003.jpg GRAPHIC 3462
7 ex99-1_004.jpg GRAPHIC 2287
8 ex99-2_001.jpg GRAPHIC 13962
9 ex99-2_002.jpg GRAPHIC 6030
10 ex99-2_003.jpg GRAPHIC 11782
11 ex99-2_004.jpg GRAPHIC 13607
12 ex99-2_005.jpg GRAPHIC 19524
13 ex99-2_006.jpg GRAPHIC 14647
14 ex99-2_007.jpg GRAPHIC 12348
15 ex99-2_008.jpg GRAPHIC 15368
  Complete submission text file 0001493152-24-043322.txt   1192977

Data Files

Seq Description Document Type Size
16 XBRL SCHEMA FILE bctx-20241101.xsd EX-101.SCH 3750
17 XBRL DEFINITION FILE bctx-20241101_def.xml EX-101.DEF 29998
18 XBRL LABEL FILE bctx-20241101_lab.xml EX-101.LAB 36631
19 XBRL PRESENTATION FILE bctx-20241101_pre.xml EX-101.PRE 27021
31 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5708
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 241419068
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)